RS64708B1 - Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala - Google Patents

Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala

Info

Publication number
RS64708B1
RS64708B1 RS20230951A RSP20230951A RS64708B1 RS 64708 B1 RS64708 B1 RS 64708B1 RS 20230951 A RS20230951 A RS 20230951A RS P20230951 A RSP20230951 A RS P20230951A RS 64708 B1 RS64708 B1 RS 64708B1
Authority
RS
Serbia
Prior art keywords
benzoimidazol
amides
channel activators
activators
channel
Prior art date
Application number
RS20230951A
Other languages
English (en)
Inventor
Lynn Resnick
George T Topalov
Steven A Boyd
Justin K Belardi
Charles A Flentge
James S Hale
Scott S Harried
David A Mareska
Kai Zhang
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of RS64708B1 publication Critical patent/RS64708B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20230951A 2014-09-12 2015-09-14 Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala RS64708B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462050023P 2014-09-12 2014-09-12
EP19185319.1A EP3572405B9 (en) 2014-09-12 2015-09-14 Benzoimidazol-1,2-yl amides as kv7 channel activators

Publications (1)

Publication Number Publication Date
RS64708B1 true RS64708B1 (sr) 2023-11-30

Family

ID=55454102

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230951A RS64708B1 (sr) 2014-09-12 2015-09-14 Benzoimidazol-1,2-il amidi kao aktivatori kv7 kanala

Country Status (13)

Country Link
US (6) US9481653B2 (sr)
EP (3) EP3572405B9 (sr)
DK (2) DK3572405T3 (sr)
ES (2) ES2749103T3 (sr)
FI (1) FI3572405T3 (sr)
HR (1) HRP20231071T1 (sr)
HU (1) HUE064331T2 (sr)
LT (1) LT3572405T (sr)
PL (1) PL3572405T3 (sr)
PT (1) PT3572405T (sr)
RS (1) RS64708B1 (sr)
SI (1) SI3572405T1 (sr)
WO (2) WO2016040952A2 (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2885424T3 (es) * 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
US9481653B2 (en) * 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
HUE063567T2 (hu) * 2018-02-20 2024-01-28 H Lundbeck As Alkoholszármazékok mint KV7 káliumcsatorna nyitók
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
BR112020018933A2 (pt) * 2018-03-19 2020-12-29 Knopp Biosciences Llc Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
WO2021041536A1 (en) * 2019-08-28 2021-03-04 Ferro Therapeutics, Inc. Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors
CN114728961A (zh) * 2019-09-17 2022-07-08 诺普生物科学有限责任公司 Kv7通道激活剂的使用方法
WO2023133256A1 (en) * 2022-01-07 2023-07-13 Biohaven Therapeutics Ltd. Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activators
WO2024054811A1 (en) * 2022-09-06 2024-03-14 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1022554A (en) 1973-03-07 1977-12-13 Haukur Kristinsson 1-carbamoyl-2-alkoxycarbonylaminoimidazo (4,5-b) pyridines
US4002623A (en) 1974-08-07 1977-01-11 Pfizer Inc. Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines
ES473201A1 (es) 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US4391811A (en) 1981-10-02 1983-07-05 Sterling Drug Inc. 2-Amino-6-(pyridinyl)-3H-imidazo[4,5-b]pyridines and their cardiotonic use
JPH0772181B2 (ja) * 1989-06-26 1995-08-02 株式会社大塚製薬工場 ベンズイミダゾール誘導体
JPH0772181A (ja) 1993-09-03 1995-03-17 Advantest Corp 電位波形測定方法および装置
GB9413724D0 (en) * 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6093728A (en) 1997-09-26 2000-07-25 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
US20030109549A1 (en) * 1999-08-05 2003-06-12 Fumitaka Ito 2-Substituted-1-piperidyl benzimidazole compounds as ORL1-receptor agonists
JP2001199968A (ja) 2000-01-18 2001-07-24 Teijin Ltd アミノベンズイミダゾール誘導体
US6384049B1 (en) 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6855714B2 (en) * 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
FR2846656B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
CA2587664A1 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
US20080146536A1 (en) 2005-08-16 2008-06-19 Pharmacopeia, Inc. 2-Aminoimidazopyridines for treating neurodegenerative diseases
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
WO2009022746A1 (ja) 2007-08-10 2009-02-19 Nippon Soda Co., Ltd. 含窒素複素環化合物および有害生物防除剤
WO2009026254A1 (en) 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
TWI482768B (zh) * 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
WO2009085230A1 (en) * 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
US20110269783A1 (en) * 2008-11-10 2011-11-03 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
RU2525116C2 (ru) * 2008-12-19 2014-08-10 Дженентек, Инк. Гетероциклические соединения и способы применения
WO2010094645A1 (en) 2009-02-17 2010-08-26 Neurosearch A/S Substituted pyridine derivatives and their medical use
EP2493895B1 (en) 2009-10-29 2017-04-26 Vectura Limited N-containing heteroaryl derivatives as jak3 kinase inhibitors
US20130165426A1 (en) 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
CN102971307A (zh) * 2010-07-08 2013-03-13 辉瑞大药厂 作为kv7钾通道开放剂的哌啶基嘧啶酰胺
SG10201505997TA (en) * 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
ES2885424T3 (es) 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
US9481653B2 (en) * 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
BR112020018933A2 (pt) * 2018-03-19 2020-12-29 Knopp Biosciences Llc Composto, composição farmacêutica, método de tratamento de um transtorno associado a kv7 e método de tratamento de um transtorno associado a uma mutação kcnq2
CN114728961A (zh) * 2019-09-17 2022-07-08 诺普生物科学有限责任公司 Kv7通道激活剂的使用方法

Also Published As

Publication number Publication date
PL3572405T3 (pl) 2023-11-13
ES2749103T3 (es) 2020-03-19
EP4289822A2 (en) 2023-12-13
FI3572405T3 (fi) 2023-09-22
US9481653B2 (en) 2016-11-01
EP3572405A1 (en) 2019-11-27
SI3572405T1 (sl) 2023-12-29
US20180148419A1 (en) 2018-05-31
EP3572405B9 (en) 2023-12-06
DK3572405T3 (da) 2023-10-16
EP4289822A3 (en) 2024-01-24
US20210188782A1 (en) 2021-06-24
EP3191457A4 (en) 2018-02-07
ES2960991T3 (es) 2024-03-07
HUE064331T2 (hu) 2024-03-28
EP3191457A2 (en) 2017-07-19
WO2018081825A1 (en) 2018-05-03
WO2016040952A2 (en) 2016-03-17
LT3572405T (lt) 2023-10-25
US20170114022A1 (en) 2017-04-27
US20160075663A1 (en) 2016-03-17
US20240300903A1 (en) 2024-09-12
HRP20231071T1 (hr) 2024-03-01
EP3191457B1 (en) 2019-07-10
US10385025B2 (en) 2019-08-20
PT3572405T (pt) 2023-10-26
WO2016040952A3 (en) 2016-05-06
US9914708B2 (en) 2018-03-13
DK3191457T3 (da) 2019-10-07
EP3572405B1 (en) 2023-07-26
US11834418B2 (en) 2023-12-05
US20200002292A1 (en) 2020-01-02
EP3572405B8 (en) 2023-09-06
US10906877B2 (en) 2021-02-02

Similar Documents

Publication Publication Date Title
HK1253372A1 (zh) 作為bace1抑制劑的2-氨基-3-氟-3-(氟甲基)-6-甲基-6-苯基-3,4,5,6-四氫吡啶
SG10201913708XA (en) Headgear clip arrangement
SI3572405T1 (sl) Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7
HK1251395A1 (zh) 用於多rat聚合的基於多用戶的分離
ZA201703498B (en) Kcnq2-5 channel activator
GB201521751D0 (en) Novel uses
EP3102364B8 (en) Tensioner
AU361320S (en) Hammock
GB2553987B (en) Near isothermal machine
GB201502252D0 (en) Carrier
GB201503023D0 (en) Chromosomal instability
GB201401978D0 (en) Hammock
PL3175066T3 (pl) Rolka
GB201509039D0 (en) Near isothermal machine
EP3181780C0 (de) Versorgungsrinne
GB2557371B (en) Millinery block
GB201517950D0 (en) Rucksacks
GB2540733B (en) Variator
GB201516198D0 (en) Rucksacks
GB201512740D0 (en) Near isothermal machine
ZA201503816B (en) Tensioning unit
GB201508318D0 (en) Variators
GB201509327D0 (en) Variator
GB201502405D0 (en) Rucksacks etc
GB201420970D0 (en) eGURE, egure, Egure